Shorted
Innate Immuno logo
IIL

Innate Immuno

Short interest
0.19%
+0.11 pp 30d
as of 27 June 2018
Reported shorts
79K
Shares on issue
41.023M

Innate Immuno (IIL) company profile

Profile, insiders and operations

Company

AI-generated research profile of Innate Immuno

biotechnology
immunotherapy
ASX
healthcare
innovation

Innate Immuno is a biotechnology company focused on developing innovative immunotherapy treatments. The company aims to address unmet medical needs by leveraging its proprietary technology to enhance the body's immune response.

Director trades

20 trades recorded

DateDirectorTypeSharesPriceValue
2025-09-08Warwick Tong
buy
---
2025-09-08Robert Peach
buy
---
2025-09-08Jane Bell
buy
---
2025-09-08Chris Burns
buy
---
2025-09-06Jane Catherine Bell
other
535,000$0.056$30,000.05
2025-09-06Warwick Bonner Tong
buy
489,000$0.072$35,000.02
2025-09-01Robert Peach
buy
892,764$0.168$150,000.02
2025-09-01Christopher John Burns
buy
533,957$0.037$20,000.11
2024-12-20Christopher John Burns
other
608,695$0.066$40,090.99
2024-12-20Jane Catherine Bell
buy
1,217,391$0.066$80,000.98
2024-12-20Robert Peach
buy
1,902,175$0.066$124,990.05
2024-12-20Warwick Bonner Tong
buy
1,217,391$0.066$80,001
2024-12-20Dr Robert Peach
buy
---
2024-12-20Ms Jane Bell
buy
---
2024-12-20Dr Warwick Tong
buy
---
2024-12-20Dr Chris Burns
buy
---
2024-08-26Christopher John Burns
exercise options
586,321$0.062$36,351.9
2024-08-26Dr Chris Burns
buy
---
2024-06-20Dr Robert Peach
buy
---
2024-06-19Dr. Robert Peach
exercise options
827,268$0.055$45,499.74

IIL intelligence dossier

Public-source evidence for this company, with industry drill-up links.

  • Tax paid and taxable income records
  • Government contracts and public money
  • Emissions and trade exposure
  • Political donations and lobbying links
Sign in to unlock the dossierFree account · no card required